China Animal Health and Epidemiology Center, Qingdao, Shandong, China.
Transbound Emerg Dis. 2019 Jul;66(4):1758-1761. doi: 10.1111/tbed.13183. Epub 2019 Apr 12.
H7N9 subtype avian influenza viruses (AIV) circulating in China over recent years have had an enormous impact on public health and economy. During the period between November 2016 and April 2017, an increase in human infections caused by these viruses was reported, with rapid emergence and spread of variants in China. Consequently, the government of China implemented a controversial vaccination strategy in September 2017. Here, we provide evidence of the prevalence of H7N9 AIVs in China based on systematic large-scale surveillance in poultry during 2013-2018. Emerging variants were confirmed as highly pathogenic in chickens using the intravenous pathogenicity index (IVPI) test. The currently available vaccine provided complete protection against the H7N9 HPAIV challenge in chickens. The collective findings clearly indicate that the vaccination strategy implemented not only significantly decreases the prevalence of H7N9 AIVs in poultry but also effectively prevents human infection with H7N9 viruses.
近年来，在中国流行的 H7N9 亚型禽流感病毒（AIV）对公共卫生和经济造成了巨大影响。在 2016 年 11 月至 2017 年 4 月期间，报告了这些病毒导致的人类感染增加，在中国迅速出现和传播了变异病毒。因此，中国政府在 2017 年 9 月实施了一项有争议的疫苗接种策略。在这里，我们提供了基于 2013 年至 2018 年期间对家禽进行的系统大规模监测的中国 H7N9 AIV 流行情况的证据。新兴变异病毒在鸡身上的静脉致病性指数（IVPI）试验中被确认为高致病性。目前可用的疫苗可完全保护鸡免受 H7N9 HPAIV 挑战。这些综合研究结果清楚地表明，实施的疫苗接种策略不仅显著降低了家禽中 H7N9 AIV 的流行率，而且有效防止了人类感染 H7N9 病毒。
